Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Ocurest AH
- Development stage
- Unknown
- Lead developer
- Centaur Pharmaceuticals
- Modality
- Small Molecules
- Administration
- Ophthalmic
01
Overview
Ocurest AH is an approved ophthalmic fixed-dose combination drug developed by Centaur Pharmaceuticals for the treatment of allergic eye diseases, such as allergic conjunctivitis, and to relieve symptoms like redness, itching, swelling, and watering of the eyes. The formulation combines five active ingredients: chlorpheniramine maleate (an antihistamine that blocks histamine H1 receptors), phenylephrine hydrochloride and naphazoline hydrochloride (vasoconstrictors/decongestants that act as alpha-adrenergic receptor agonists to reduce redness and swelling), and camphor and menthol (which provide a cooling and soothing effect to alleviate minor eye irritation).
- Brand names
- Ocurest AHOcurest AH Eye DropsOcurest AH New Eye DropsOcurest New Eye DropsOcurest Plus Neo Eye Drops
- Other names
- Ocurest-AHOcurest-AH Eye Drops
02
Targets
ADRA1A (α1A)ADRA2A (α2A)ADRA1 (Alpha-1 adrenergic receptor family)HRH1 (Histamine H1 Receptor)TRPM8 (Transient receptor potential cation channel subfamily M member 8)TRPV3 (Transient receptor potential vanilloid subtype 3)
Beyond the preview
Go deeper on Ocurest AH.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Ocurest AH.